Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-21-039319
Filing Date
2021-10-05
Accepted
2021-10-05 19:38:29
Documents
1
Period of Report
2021-10-05

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 21720
  Complete submission text file 0000899243-21-039319.txt   23119
Mailing Address C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1800 CHICAGO IL 60601
Business Address
JOHNSON KENNETH ERLAND (Reporting) CIK: 0001743774 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40880 | Film No.: 211308376

Mailing Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601
Business Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601 844-445-5704
Xeris Biopharma Holdings, Inc. (Issuer) CIK: 0001867096 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations